Skip Nav Destination
Issues
1 November 2000
ISSN 1078-0432
EISSN 1557-3265
Advances in Brief
Clinical Trials
Clinical Phase I Dose Escalation and Pharmacokinetic Study of High-Dose Chemotherapy with Treosulfan and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Malignancies1
Max E. Scheulen; Ralf A. Hilger; Carsten Oberhoff; Jochen Casper; Matthias Freund; Klaus M. Josten; Martin Bornhäuser; Gerhard Ehninger; Wolfgang E. Berdel; Joachim Baumgart; Andreas Harstrick; Peter Bojko; Hans-Heinrich Wolf; Adolf E. Schindler; Siegfried Seeber
Molecular Oncology, Markers, Clinical Correlates
Human Herpesvirus 8 Open Reading Frame 26 and Open Reading Frame 65 Sequences from Multiple Myeloma Patients: A Shared Pattern Not Found in Kaposi’s Sarcoma or Primary Effusion Lymphoma1
Hong J. Ma; Nelida N. Sjak-Shie; Robert A. Vescio; Marissa Kaminsky; Amy Mikail; Mehis Pold; Kimberly Parker; Meral Beksac; Daniel Belson; Thomas J. Moss; Chun H. Wu; Jin Zhou; Lan Zhang; Grace Chen; Jonathan W. Said; James R. Berenson
Expression and Prognostic Value of Wilms’ Tumor 1 and Early Growth Response 1 Proteins in Nephroblastoma
Mazen A. Ghanem; Theo H. Van der Kwast; Jan C. Den Hollander; Mondastri K. Sudaryo; Monique H. A. Oomen; Marinus A. Noordzij; Marry M. Van den Heuvel; Shoukri M. Nassef; Rien M. Nijman; Gert J. Van Steenbrugge
Experimental Therapeutics, Preclinical Pharmacology
Antitumor Activity of Combined Treatment of Human Cancer Cells with Ionizing Radiation and Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 plus Type I Protein Kinase A Antisense Oligonucleotide1
Cataldo Bianco; Roberto Bianco; Giampaolo Tortora; Vincenzo Damiano; Patrizia Guerrieri; Paolo Montemaggi; John Mendelsohn; Sabino De Placido; A. Raffaele Bianco; Fortunato Ciardiello
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.